Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Staar Surgical TICL

This article was originally published in The Gray Sheet

Executive Summary

Receipt of CE mark for toric implantable contact lens EU sales makes Staar's TICL the first posterior phakic intraocular lens able to reduce pre-existing astigmatism alongside myopia or hyperopia correction, the company says Dec. 3. The Monrovia, Calif. firm gained conditional IDE clearance in January for a 125-patient U.S. trial investigating the TICL to treat myopia of -3.0 to 20 diopters - and astigmatism of 1.0 to 4.0 D (1"The Gray Sheet" Jan. 14, 2002, In Brief). Staar implanted the first device in a U.S. patient's eye in August, with "excellent results [and] no surprises"...

You may also be interested in...



Staar Surgical TICL

Toric implantable contact lens gains conditional investigational device exemption clearance for a 125-patient U.S. trial to treat myopia of -3.0 to -20 diopters and astigmatism of 1.0 to 4.0 diopters. The device "is the only phakic intraocular lens" for pre-existing astigmatism and myopia, Staar says. An ongoing U.S. study of a non-toric myopia version, including 529 enrolled cases, shows a 2.3% incidence of lens opacities, with eight of the 12 opacities being "non progressive and showing no loss of best-corrected visual acuity," Staar notes...

Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne

Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.

Real-World Evidence Fails Another Test At US FDA

Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.

UsernamePublicRestriction

Register

MT017605

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel